NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/11/2023
Back to search
Official data from USPTO
ACCRETAMAB
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
26
Latest update
07/11/2023
Trademark type
Word
Nice classes
5
Filing date
07/06/2021
Registration date
07/11/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/11/2023
Last transaction
07/11/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
Tokyo, JP
Examiner
MESSICK, TABITHA LEE
Law office
L40
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Kyowa Kirin Co., Ltd.
Representatives
Kaushal Odedra ODEDRA LAW OFFICE, PLLC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Host cells for medical or clinical use; cells for medical usecells that manufacture antibodiesfragments of antibodies or derivatives of antibodies for medical or clinical use; cells for medical usetransfected cells that manufacture antibodiesfragments of antibodies or derivatives of antibodies for medical or clinical use; pharmaceuticalscentral nervous system depressantspreparations for ophthalmic useanti-histaminicscardiotonicsarrhythmia treating agentsdiureticshypotensors being pharmaceutical products for treatment of blood pressureprophylactic for the treatment of asthmaantitussives and expectorantsstomachics and digestives for pharmaceutical purposesantacidshormones in the nature of pituitary hormones for the treatment of infertilitythyroid hormones for the treatment of hyperthyroidismanabolic hormones for the treatment of aplastic anemia and osteoporosis; pharmaceuticalscorticosteroids for treatment of hypopituitarismof congenital adrenal hyperplasiaof rheumatoid arthritisof rheumatic feverof crohn's diseaseof chronic active hepatitis; pharmaceuticalsestrogen preparations and progesterone used as combined oral contraceptivesurinary antisepticsanalgesicsanti-itching agents; pharmaceuticalscataplasms being medical plasters for the treatment of bruiseslumbago and stiff shoulder; pharmaceuticalspharmaceutical preparations used to treat hair disordersvitamin preparationsfood enriching agents in the nature of vitamins for treating vitamin deficienciesanti-coagulantsenzyme preparations for medical purposes for control of malabsorption and diarrheaanti-cancer preparationsanti-sarcoma preparationsantibiotics and their preparations for the treatment of infectious diseasesantituberculotic agentsinfluenza vaccinesdiphtheria vaccinestetanus vaccinesgas gangrene vaccinesJapanese encephalitis vaccinesin vitro tetrodotoxines for medical useantiprotozoals for the treatment of trichomoniasis and dermatophytosisanthelmintics for the treatment of threadworm and toxoplasmaosisnaturally occurring drugs delivery agents in the form of capsulesliquidspowderspatches for treating peptic ulcerscharred drugs delivery agents in the form of capsulesliquidspowderspatches for treating peptic ulcersmoxa in the nature of cone or stick made of ground mugwort leaves for treating peptic ulcers; pharmaceuticalsveterinary drugs for the treatment of distemper in dogsdistomatosis in dogscoccidian in chickensdysentery in pigs; pharmaceuticalsgermination controllers and plant rearing agents in the nature of herbicidesfungicidesinsecticidesbactericides and rodenticides for domestic and agricultural use; pharmaceuticalsantisepticspharmaceutical drugs in the nature of drug delivery agents in the form of coatings for tablets for the treatment of arteriosclerosisoncostatic drugs in the nature of pharmaceutical products for the treatment for cancermultienzyme digestants for pharmaceutical in vivo useantifungal antibiotics for treating trichomoniasis and dermatophytosisdrugs in the nature of pharmaceutical products for the prevention and treatment of parkinsonismminor tranquilizersanti anxiety agents; pharmaceuticalsmedicinal preparations for the treatment of the central nervous systemthe respiratory tract and the cardiovascular system; pharmaceuticalsanti-bacterial preparations in the nature of antibacterial substances for medical purposesmonolithic preparations in the nature of substances for medical purposesmedicinal preparations for the treatment of peptic ulcersanti-inflammatory preparationsanalgesic preparationscephalosporincocarboxylase preparationsglutathione preparations in the nature of radioactive substances and nutritive substances for microorganisms for medical purposespharmaceutical preparations for improving the metabolism and the peripheral circulationblood plasma in the nature of plasma substitutes and extracorporeal circulation flow improvement preparationsdiuretic and anti-hypertensive preparationsin vitro diagnostic reagents for medical usein vitro extra corporeal diagnostic reagents for medical usein vitro x-ray contrast agents for medical usein vitro diagnostic media for medical usepharmaceutical preparations for the treatment of insomnia and other sleep related diseases; all the foregoing pharmaceuticals and vaccines comprising monoclonal antibodies
Publications
History of USPTO decisions and trademark events.
26 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
07/11/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/25/2023
PUBO
PUBLISHED FOR OPPOSITION
04/25/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/05/2023
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
03/17/2023
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
03/10/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/07/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/14/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/14/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/14/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/31/2022
GNRT
NON-FINAL ACTION E-MAILED
08/31/2022
CNRT
NON-FINAL ACTION WRITTEN
08/31/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/30/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/29/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/29/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/16/2022
GNRT
NON-FINAL ACTION E-MAILED
02/16/2022
CNRT
NON-FINAL ACTION WRITTEN
02/16/2022
DOCK
ASSIGNED TO EXAMINER
02/09/2022
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
09/20/2021
ALIE
ASSIGNED TO LIE
09/17/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/14/2021
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
07/21/2021
NWAP
NEW APPLICATION ENTERED
07/09/2021
Continuous trademark protection
Get notified about every new filing that threatens ACCRETAMAB or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.